TY - JOUR
T1 - Protection of ovarian function by two distinct methods of ovarian shielding for young female patients who receive total body irradiation
AU - Kanda, Yoshinobu
AU - Wada, Hidenori
AU - Yamasaki, Ryoko
AU - Kawamura, Koji
AU - Ishihara, Yuko
AU - Sakamoto, Kana
AU - Ashizawa, Masahiro
AU - Sato, Miki
AU - Machishima, Tomohito
AU - Terasako-Saito, Kiriko
AU - Kimura, Shun Ichi
AU - Nakasone, Hideki
AU - Kikuchi, Misato
AU - Yamazaki, Rie
AU - Kanda, Junya
AU - Kako, Shinichi
AU - Nishida, Junji
AU - Tsunoda, Hidekazu
AU - Omori, Yoshio
AU - Nakazawa, Masanori
AU - Tanaka, Osamu
PY - 2014/2
Y1 - 2014/2
N2 - To prevent ovarian dysfunction due to total body irradiation, we started ovarian shielding at our center (Saitama Medical Center, Jichi Medical University (SMC-JMU)) with a long source axis distance, which is different from the original method used at the University of Tokyo Hospital (UTH). We retrospectively analyzed the outcome of eight patients with a median age of 20.5 years from SMC-JMU and compared the results with the published data for eight patients with a median age of 22 years from UTH. The recovery of ovarian function was observed in five and six patients, respectively. The cumulative incidence of ovarian recovery, while treating relapse and death without ovarian recovery as competing risks, was 68.8 % at 2 years after transplantation in the total population, and there was no statistically significant difference between the two institutions (p = 0.85). Age and the history of previous chemotherapy did not affect the incidence of ovarian recovery. Two patients from each center had a relapse of leukemia. Overall, among the 11 patients who have survived without relapse, only one has not achieved ovarian recovery. In conclusion, ovarian shielding with both methods strongly protected ovarian function. However, we should continue to monitor the relapse rate among patients who undergo this procedure.
AB - To prevent ovarian dysfunction due to total body irradiation, we started ovarian shielding at our center (Saitama Medical Center, Jichi Medical University (SMC-JMU)) with a long source axis distance, which is different from the original method used at the University of Tokyo Hospital (UTH). We retrospectively analyzed the outcome of eight patients with a median age of 20.5 years from SMC-JMU and compared the results with the published data for eight patients with a median age of 22 years from UTH. The recovery of ovarian function was observed in five and six patients, respectively. The cumulative incidence of ovarian recovery, while treating relapse and death without ovarian recovery as competing risks, was 68.8 % at 2 years after transplantation in the total population, and there was no statistically significant difference between the two institutions (p = 0.85). Age and the history of previous chemotherapy did not affect the incidence of ovarian recovery. Two patients from each center had a relapse of leukemia. Overall, among the 11 patients who have survived without relapse, only one has not achieved ovarian recovery. In conclusion, ovarian shielding with both methods strongly protected ovarian function. However, we should continue to monitor the relapse rate among patients who undergo this procedure.
KW - Fertility
KW - Hematopoietic stem cell transplantation
KW - Ovarian function
KW - Shielding
KW - Total body irradiation
UR - http://www.scopus.com/inward/record.url?scp=84895060587&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84895060587&partnerID=8YFLogxK
U2 - 10.1007/s00277-013-1852-8
DO - 10.1007/s00277-013-1852-8
M3 - Article
C2 - 23892927
AN - SCOPUS:84895060587
SN - 0939-5555
VL - 93
SP - 287
EP - 292
JO - Annals of Hematology
JF - Annals of Hematology
IS - 2
ER -